Madrigal Pharmaceuticals Inc
$ 497.27
-3.62%
29 May - close price
- Market Cap 12,109,754,000 USD
- Current Price $ 497.27
- High / Low $ 520.30 / 496.62
- Stock P/E N/A
- Book Value 23.59
- EPS -13.51
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.49 %
- 52 Week High 615.00
- 52 Week Low 268.69
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Analyst Target Price
$679.29
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-19 | 2025-11-04 | 2025-08-05 | 2025-05-01 | 2025-02-26 | 2024-10-31 | 2024-08-07 | 2024-05-07 | 2024-02-28 | 2023-11-06 | 2023-08-08 |
| Reported EPS | -1.38 | -2.57 | -4.96 | -1.9 | -3.32 | -2.71 | -4.92 | -7.1 | -7.38 | -5.68 | -5.34 | -4.69 |
| Estimated EPS | -4.14 | -0.6039 | -1.99 | -3.53 | -3.79 | -4.1246 | -6.91 | -7.66 | -6.28 | -5.34 | -4.93 | -4.54 |
| Surprise | 2.76 | -1.9661 | -2.97 | 1.63 | 0.47 | 1.4146 | 1.99 | 0.56 | -1.1 | -0.34 | -0.41 | -0.15 |
| Surprise Percentage | 66.6667% | -325.5671% | -149.2462% | 46.1756% | 12.4011% | 34.2967% | 28.7988% | 7.3107% | -17.5159% | -6.367% | -8.3164% | -3.304% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDGL
2026-05-28 16:10:05
Madrigal Pharmaceuticals (MDGL) is gaining attention following new Phase 3 and real-world data for its MASH drug, Rezdiffra. Despite its recent 90-day share price increase of 18.35%, the stock has declined 11.15% year-to-date, though it shows a strong 94.81% 1-year total shareholder return. Simply Wall St's analysis suggests Madrigal is 21.4% undervalued, with a fair value target of $671.07 per share, driven by expectations of rapid revenue expansion and earnings growth.
2026-05-27 15:09:45
Madrigal Pharmaceuticals announced that new data on its drug Rezdiffra indicate it can reduce cardiovascular and liver-related risks in patients with MASH. This finding was presented at Digestive Disease Week 2024. The data reinforces Rezdiffra's potential beyond just liver histology improvement.
2026-05-27 11:40:43
Madrigal Pharmaceuticals announced that its drug Rezdiffra significantly reduced markers of cardiovascular and liver-related risk in patients with MASH, according to Phase 3 and real-world data presented at EASL Congress 2026. The data showed improvements in atherogenic lipids like LDL-C, ApoB, and Lp(a), as well as reductions in ANTICIPATE-NASH risk scores and liver stiffness, irrespective of statin use. These findings reinforce Rezdiffra's role as a foundational therapy for MASH, a disease where cardiovascular complications are the leading cause of death.
2026-05-27 11:40:43
Madrigal Pharmaceuticals announced new data from Phase 3 trials and real-world evidence showing that Rezdiffra (resmetirom) significantly reduced markers of cardiovascular and liver-related risk in patients with MASH. The data, presented at EASL Congress 2026, highlighted improvements in atherogenic lipid profiles and a risk score for liver-related events in patients with well-compensated MASH cirrhosis. Multiple real-world analyses further supported Rezdiffra’s effectiveness in improving cardiometabolic parameters, liver biomarkers, and stiffness over time.
2026-05-26 08:10:15
An insider at Madrigal Pharmaceuticals recently sold shares totaling $2,928,716, as disclosed in a recent SEC filing. This transaction indicates a significant insider sale at the company.
2026-05-25 17:41:12
Madrigal Pharmaceuticals presented new Rezdiffra data at EASL 2026, focusing on non-invasive risk stratification and real-world effectiveness for MASH and compensated cirrhosis. While this data strengthens the case for non-invasive monitoring, it doesn't significantly alter the immediate investment focus on confirmatory trial outcomes, payer behavior, and safety signals. Investors should continue to monitor these factors, along with potential reimbursement pressures and competitive threats, despite the promising new insights.
